Jesse Lyons, MD
Family Medicine · Jacksonville, FLNPI 1437716529
Payments from drug & device makers
Across 199 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$577
- AbbVie$522
- Pfizer$468
- Novo Nordisk$441
- Lilly USA, LLC$202
- Astellas Pharma US Inc$175
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,83197%
- Education$993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $577 |
| AbbVie | 29 | $522 |
| Pfizer | 32 | $468 |
| Novo Nordisk | 29 | $441 |
| Lilly USA, LLC | 11 | $202 |
| Astellas Pharma US Inc | 5 | $175 |
| Exact Sciences | 7 | $147 |
| GSK | 6 | $132 |
| Amgen | 6 | $110 |
| Otsuka America Pharmaceutical, Inc. | 4 | $103 |
| Lundbeck LLC | 3 | $86 |
| Johnson & Johnson | 3 | $70 |
| Merck | 4 | $69 |
| Teva Pharmaceuticals USA, Inc. | 3 | $65 |
| Hologic Sales And Service, LLC | 2 | $60 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Dynavax Technologies Corporation | 2 | $46 |
| Bayer | 3 | $44 |
| Shield Therapeutics Inc | 2 | $44 |
| Impel Pharmaceuticals LLC | 2 | $43 |
| Boston Scientific | 1 | $43 |
| Noven Therapeutics, LLC | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Boehringer Ingelheim | 2 | $38 |
| Avanos Medical | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Medtronic | 1 | $26 |
| Abbott | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $22 |
| Dexcom, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| La Jolla Pharmaceutical Company | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$120
How this compares
$3,930 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 73 | $89,711 |
| MounjaroTirzepatide | 49 | $63,379 |
| OzempicSemaglutide | 46 | $58,785 |
| JanuviaSitagliptin Phosphate | 44 | $57,084 |
| JardianceEmpagliflozin | 27 | $36,129 |
| EliquisApixaban | 22 | $31,524 |
| TrulicityDulaglutide | 30 | $29,777 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $27,102 |
| MyrbetriqMirabegron | 20 | $20,119 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $9,133 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $8,065 |
| Repatha SureclickEvolocumab | 12 | $6,474 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,747 |
| Rosuvastatin Calcium | 260 | $3,335 |
| Gabapentin | 105 | $2,347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $577 | $103,592106 claims |
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $202 | $93,67398 claims |
| Novo NordiskOzempic | $441 | $58,78546 claims |
| MerckJanuvia | $69 | $57,08444 claims |
| Boehringer IngelheimJardiance | $38 | $36,12927 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $132 | $35,16654 claims |
| PfizerEliquis | $468 | $31,52422 claims |
| Astellas Pharma US IncMyrbetriq | $175 | $20,11920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Jacksonville
- Jeffry JacqmeinJacksonville$8.7M
- Herman DowneyJacksonville$4.1M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.